349 related articles for article (PubMed ID: 26580395)
1. von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy.
Nishigori N; Matsumoto M; Koyama F; Hayakawa M; Hatakeyayama K; Ko S; Fujimura Y; Nakajima Y
PLoS One; 2015; 10(11):e0143136. PubMed ID: 26580395
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
[TBL] [Abstract][Full Text] [Related]
3. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab.
Hubert C; Sempoux C; Humblet Y; van den Eynde M; Zech F; Leclercq I; Gigot JF
HPB (Oxford); 2013 Nov; 15(11):858-64. PubMed ID: 23458554
[TBL] [Abstract][Full Text] [Related]
4. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
5. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
Robinson SM; Mann J; Vasilaki A; Mathers J; Burt AD; Oakley F; White SA; Mann DA
J Hepatol; 2013 Aug; 59(2):318-26. PubMed ID: 23624001
[TBL] [Abstract][Full Text] [Related]
7. Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy: Potential Markers for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome.
Park S; Kim HY; Kim H; Park JH; Kim JH; Kim KH; Kim W; Choi IS; Jung YJ; Kim JS
Medicine (Baltimore); 2016 Jan; 95(2):e2454. PubMed ID: 26765438
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
9. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation.
Park YD; Yoshioka A; Kawa K; Ishizashi H; Yagi H; Yamamoto Y; Matsumoto M; Fujimura Y
Bone Marrow Transplant; 2002 May; 29(9):789-94. PubMed ID: 12040478
[TBL] [Abstract][Full Text] [Related]
10. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
Viganò L; Capussotti L; De Rosa G; De Saussure WO; Mentha G; Rubbia-Brandt L
Ann Surg; 2013 Nov; 258(5):731-40; discussion 741-2. PubMed ID: 24045448
[TBL] [Abstract][Full Text] [Related]
11. Sinusoidal dilation increases the risk of complications in hepatectomy for CRCLM - Protective effect of bevacizumab and diabetes mellitus, serum gamma-glutamyltranspeptidase as predictive factor.
Martins J; Alexandrino H; Oliveira R; Cipriano MA; Falcão D; Ferreira L; Martins R; Serôdio M; Martins M; Tralhão JG; Prado e Castro L; Castro E Sousa F
Eur J Surg Oncol; 2016 May; 42(5):713-21. PubMed ID: 26972374
[TBL] [Abstract][Full Text] [Related]
12. Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.
Kim MJ; Han SW; Lee DW; Cha Y; Lee KH; Kim TY; Oh DY; Kim SH; Im SA; Bang YJ; Kim TY
Cancer Res Treat; 2016 Jul; 48(3):990-7. PubMed ID: 26790967
[TBL] [Abstract][Full Text] [Related]
13. Ischaemia-reperfusion injury with Pringle's maneuver induces unusually large von Willebrand factor multimers after hepatectomy.
Yoshikawa T; Nomi T; Sakai K; Hayakawa M; Hokuto D; Matsuo Y; Sho M; Matsumoto M
Thromb Res; 2019 Nov; 183():20-27. PubMed ID: 31518960
[TBL] [Abstract][Full Text] [Related]
14. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Rather M; Rosso E; Addeo P; Jaeck D; Bachellier P
Ann Surg Oncol; 2012 Jul; 19(7):2230-7. PubMed ID: 22402811
[TBL] [Abstract][Full Text] [Related]
15. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
16. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.
Rubbia-Brandt L; Lauwers GY; Wang H; Majno PE; Tanabe K; Zhu AX; Brezault C; Soubrane O; Abdalla EK; Vauthey JN; Mentha G; Terris B
Histopathology; 2010 Mar; 56(4):430-9. PubMed ID: 20459550
[TBL] [Abstract][Full Text] [Related]
17. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases.
Vreuls CP; Van Den Broek MA; Winstanley A; Koek GH; Wisse E; Dejong CH; Olde Damink SW; Bosman FT; Driessen A
Histopathology; 2012 Aug; 61(2):314-8. PubMed ID: 22571348
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
[TBL] [Abstract][Full Text] [Related]
19. Von Willebrand Factor Deposition and ADAMTS-13 Consumption in Allograft Tissue of Thrombotic Microangiopathy-like Disorder After Living Donor Liver Transplantation: A Case Report.
Nakanuma S; Miyashita T; Hayashi H; Ohbatake Y; Takamura H; Okazaki M; Yamaguchi T; Sakai S; Makino I; Oyama K; Tajima H; Ninomiya I; Fushida S; Ohta T
Transplant Proc; 2017 Sep; 49(7):1596-1603. PubMed ID: 28651806
[TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Duwe G; Knitter S; Pesthy S; Beierle AS; Bahra M; Schmelzle M; Schmuck RB; Lohneis P; Raschzok N; Öllinger R; Sinn M; Struecker B; Sauer IM; Pratschke J; Andreou A
Eur J Surg Oncol; 2017 Sep; 43(9):1668-1681. PubMed ID: 28599872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]